This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

59/100

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Tau biomarkers

Topic: Risk, prevention and care in population studies

Objective To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of dementia. Methods Baseline CSF was collected from 512 patients with Alzheimer disease (AD) and 272 patients with other types of dementia (OD), 135 patients with a psychiatric disorder (PSY), and 275 patients with subjective memory complaints (SMC). Aβ42, t-tau, and p-tau (at amino acid 181) were measured in CSF by ELISA.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Schoonenboom, N. S., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., et al. (2012). Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. https://doi.org/10.1212/wnl.0b013e31823ed0f0

Vancouver

Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012. doi:10.1212/wnl.0b013e31823ed0f0. PMID: 22170879.

BibTeX

@article{schoonenboom2012-22170879,
  author  = {Schoonenboom, N. S. and Reesink, F. E. and Verwey, N. A. and Kester, M. I. and Teunissen, C. E. and van de Ven, P. M. and Pijnenburg, Y. A. and Blankenstein, M. A. and others},
  title   = {{Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort}},
  journal = {Neurology},
  year    = {2012},
  doi     = {10.1212/wnl.0b013e31823ed0f0},
  pmid    = {22170879},
  url     = {https://doi.org/10.1212/wnl.0b013e31823ed0f0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Methods Baseline CSF was collected from 512 patients with Alzheimer disease (AD) and 272 patients with other types of dementia (OD), 135 patients with a psychiatric disorder (PSY), and 275 patients with subjective memory complaints (SMC).
Aβ42, t-tau, and p-tau (at amino acid 181) were measured in CSF by ELISA.
Autopsy was obtained in a subgroup of 17 patients.
Results A correct classification of patients with AD (92%) and patients with OD (66%) was accomplished when CSF Aβ42 and p-tau were combined.

Why it matters

This study measured amyloid-beta 42, total tau, and phosphorylated tau in cerebrospinal fluid from a large memory clinic cohort to see how these markers behave across different types of dementia. It found that a combination of amyloid-beta 42 and phosphorylated tau correctly classified 92% of Alzheimer patients and 66% of those with other dementias, which is a diagnostic result only.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants512
Evidence strengthModerate

How this study scored 59/100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Neurology)
Journal's citation record	4 / 4	Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2012 — within 20 year(s) of the newest study here
Sample size	2 / 4	512 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	6 / 7	Cited 304 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	19.0 citations a year over 16 year(s) since 2012
Impact for its field and year	4 / 6	Cited 16.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	4 / 6	Cited by 30 other studies in this library
Still being cited	2 / 4	Cited 38 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Wiesje M. van der Flier: h-index 132 (OpenAlex, whole career)
Institution's track record	1 / 3	Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 22170879)
Free to read	0 / 2	Behind a paywall — scores zero
Total	59 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers

Also tagged “cerebrospinal”

822 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 822 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →